23-Mar-2026
SAB BIO Closes $85 Million Public Offering to Propel Development of T1D Therapy
Market Chameleon (Fri, 20-Mar 7:26 AM ET)
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Thu, 19-Mar 4:01 PM ET)
SAB Biotherapeutics Launches Major Equity Financing Offering
TipRanks (Thu, 19-Mar 6:30 AM ET)
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Tue, 17-Mar 10:46 PM ET)
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Tue, 17-Mar 4:01 PM ET)
Market Chameleon (Wed, 11-Mar 6:34 AM ET)
Globe Newswire (Tue, 10-Mar 7:31 AM ET)
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
Globe Newswire (Mon, 9-Mar 5:16 PM ET)
SAB BIO to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Mar 9:00 AM ET)
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
Globe Newswire (Wed, 7-Jan 8:00 AM ET)
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. The company's candidate, SAB-142 is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of type 1 diabetes (T1D).
Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.
As of March 23, 2026, SABS stock price climbed to $3.93 with 513,374 million shares trading.
SABS has a beta of 1.42, meaning it tends to be more sensitive to market movements. SABS has a correlation of 0.09 to the broad based SPY ETF.
SABS has a market cap of $276.18 million. This is considered a Small Cap stock.
Last quarter Sab Biotherapeutics reported $0 in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-249,998 and missed earnings estimates by -$.13.
In the last 3 years, SABS traded as high as $14.50 and as low as $1.00.
The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, VXF, AVSC.
SABS has outperformed the market in the last year with a price return of +128.5% while the SPY ETF gained +17.5%. SABS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2.3% and +2.3%, respectively, while the SPY returned -4.5% and -3.1%, respectively.
SABS support price is $3.53 and resistance is $3.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.
